http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
CORRECTING and REPLACING --Merus Provides 2023 Outlook
-
Merus N.V. (MRUS) Provides 2023 Outlook
-
Merus Provides 2023 Outlook
-
Merus Provides 2023 Outlook
-
Merus to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference
-
Merus to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference
-
Merus Announces Financial Results for the Third Quarter and Provides Business Update
-
Merus Announces Financial Results for the Third Quarter and Provides Business Update
-
Merus N.V. (MRUS) Presents First in Human Data on MCLA-129
-
Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
-
Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
-
Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
-
Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
-
Merus Announces Poster Presentation on MCLA-129 at the 34th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics
-
Merus Announces Poster Presentation on MCLA-129 at the 34th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics
-
Merus to Participate in a Panel Discussion at Citi's 17th Annual BioPharma Conference
-
Merus to Participate in a Panel Discussion at Citi's 17th Annual BioPharma Conference
-
Merus Announces Financial Results for the Second Quarter and Provides Business Update
-
Merus Announces Financial Results for the Second Quarter and Provides Business Update
-
Merus N.V. (MRUS) Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancer
-
Merus Presents Clinical Data on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Oral Abstract)
-
Merus Presents Clinical Data on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Oral Abstract)
-
Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference
-
Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference
-
Merus Announces Publication of Abstract of Zenocutuzumab in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Merus Announces Publication of Abstract of Zenocutuzumab in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Merus to Present at the H.C. Wainwright Global Investment Conference
-
Merus to Present at the H.C. Wainwright Global Investment Conference
-
Merus Announces Financial Results for the First Quarter 2022 and Provides Business Update
-
Merus Announces Financial Results for the First Quarter 2022 and Provides Business Update
-
Zenocutuzumab Clinical Abstract Selected for Oral Presentation at the 2022 American Society of Clinical Oncology Annual Meeting
-
Zenocutuzumab Clinical Abstract Selected for Oral Presentation at the 2022 American Society of Clinical Oncology Annual Meeting
-
Merus Announces Publication in Nature Cancer on Petosemtamab’s (MCLA-158) Unique Mechanism of Action
-
Merus Announces Publication in Nature Cancer on Petosemtamab’s (MCLA-158) Unique Mechanism of Action
-
Merus Presents Preclinical Data on MCLA-129 at the American Association for Cancer Research Annual Meeting 2022
-
Merus Presents Preclinical Data on MCLA-129 at the American Association for Cancer Research Annual Meeting 2022
-
Merus to Participate in a Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference
-
Merus to Participate in a Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference
-
Merus Announces Publication of Abstract on MCLA-129 at the American Association for Cancer Research 2022 Annual Meeting
-
Merus Announces Publication of Abstract on MCLA-129 at the American Association for Cancer Research 2022 Annual Meeting
-
Merus Announces Financial Results for the Fourth Quarter and Full Year 2021 and Provides Business Update
-
Merus Announces Financial Results for the Fourth Quarter and Full Year 2021 and Provides Business Update
-
Merus to Participate in Upcoming Investor Conferences
-
Merus to Participate in Upcoming Investor Conferences
-
Merus N.V. (MRUS) Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145
-
Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145
-
Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145
-
Merus N.V. (MRUS) Presents Updates Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine in Patients with HER2+ Metastatic Breast Cancer
-
Merus Presents Updated Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine in Patients with HER2+ Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
-
Merus Presents Updated Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine in Patients with HER2+ Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium

